Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 607Lung Neoplasms 190Neoplasms 68Neoplasm Metastasis 46Mesothelioma, Malignant 46Adenocarcinoma of Lung 42Mesothelioma 40Colorectal Neoplasms 29Carcinoma 23Breast Neoplasms 23Parkinson Disease 4, Autosomal Dominant Lewy Body 21Meningeal Carcinomatosis 20Head and Neck Neoplasms 19Brain Neoplasms 18Ovarian Neoplasms 17Adenocarcinoma 15Small Cell Lung Carcinoma 14NSCLC 14Pancreatic Neoplasms 12Melanoma 12Squamous Cell Carcinoma of Head and Neck 11Recurrence 11Lung Diseases 10Carcinoma, Transitional Cell 10Uterine Cervical Neoplasms 9Neoplasms by Site 9Adenocarcinoma, Bronchiolo-Alveolar 9Thoracic Neoplasms 8Non-squamous Non-small Cell Lung Cancer 8Carcinoma, Bronchogenic 8

Interventions

Pemetrexed 1Immune Checkpoint Inhibitors 1Carboplatin 1Angiogenesis Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Non-squamous Non-small Cell Lung Cancer × Pemetrexed × Clear all
NCT05346952 2022-04-26

A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Unknown
390 enrolled
Thoracic

Advanced Non-squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡